Artichoke By-products Rich in Hydroxycinnamic Acids and Mediterranean Diet for Type 2 Diabetes Prevention.

Type 2 diabetes (T2D) and obesity represent major global public health challenges, largely driven by insulin resistance and excess body weight. Lifestyle interventions based on energy-restricted Mediterranean dietary patterns have demonstrated beneficial effects on glycemic control and body weight; however, substantial interindividual variability in response persists. Emerging evidence suggests that specific dietary bioactive compounds, such as hydroxycinnamic acids (HCAs), may play a relevant role in improving insulin sensitivity, yet their contribution within structured dietary interventions remains insufficiently explored.

In this context, the hypothesis of the present study is that daily supplementation with an artichoke by-product powder rich in bioavailable HCAs, administered within an energy-restricted Mediterranean diet (erMeDiet), will lead to greater improvements in insulin resistance and body weight compared with an erMeDiet alone in overweight and obese adults with insulin resistance. Furthermore, interindividual variability in response to HCAs is hypothesized to be partially explained by differences in metabolic, microbiota-related, and epigenetic profiles.

Following recruitment and screening, the study will consist of a 16-week randomized, controlled, double-blind, parallel-group lifestyle intervention. Participants will be randomly assigned (1:1) to one of two intervention arms:

Intervention group: Energy-restricted Mediterranean diet (approximately -500 kcal/day) combined with physical activity counselling and daily supplementation with an artichoke by-product powder providing a minimum of 600 mg/day of bioavailable hydroxycinnamic acids.

Control group: Energy-restricted Mediterranean diet and identical physical activity counselling, supplemented with an isocaloric placebo powder matched for macronutrient composition but devoid of HCAs.

All participants will receive individualized dietary counselling and guidance to achieve at least 150 minutes per week of moderate-intensity physical activity. Clinical visits will be conducted at baseline and throughout the intervention to monitor adherence, collect biological samples, and assess outcomes.

The primary outcomes of the study are changes in insulin resistance, assessed by the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), and changes in body weight after 16 weeks of intervention. Secondary outcomes include changes in anthropometric parameters, glucose metabolism markers, lipid profile, inflammatory and oxidative stress markers, dietary intake, physical activity, and continuous glucose monitoring metrics.

In addition, a comprehensive multi-omics approach will be applied to investigate the biological mechanisms underlying the effects of HCAs. This includes targeted and untargeted metabolomics, gut microbiota metagenomics, and genome-wide DNA methylation analyses. Machine learning methods will be used to integrate clinical and omics data in order to identify biomarkers predictive of individual response to the intervention, contributing to the advancement of precision nutrition strategies for T2D prevention.

This study aims to provide robust clinical and mechanistic evidence supporting the use of sustainable, upcycled plant-based bioactive compounds as complementary dietary tools for improving insulin resistance and preventing type 2 diabetes in high-risk populations.

• Fasting glucose (mmol/L) [Срок оценки: From enrollment to the end of treatment at 16 weeks.]
• Fasting insulin (µU/mL) [Срок оценки: From enrollment to the end of treatment at 16 weeks.]
• HbA1c (%) [Срок оценки: From enrollment to the end of treatment at 16 weeks.]
• HOMA-IR Index [Срок оценки: From enrollment to the end of treatment at 16 weeks.]
• HOMA-B index [Срок оценки: From enrollment to the end of treatment at 16 weeks.]
• Gut microbial diversity [Срок оценки: From enrollment to the end of treatment at 16 weeks.]
• Gut microbiota taxonomic composition [Срок оценки: From enrollment to the end of treatment at 16 weeks.]
• Microbial functional pathways related to metabolic health [Срок оценки: From enrollment to the end of treatment at 16 weeks.]
• Urinary polyphenol-derived metabolites (mmol/24 h). [Срок оценки: From enrollment to the end of treatment at 16 weeks.]
• Urinary metabolomic profile [Срок оценки: From enrollment to the end of treatment at 16 weeks.]
• Epigenome-wide DNA methylation analysis [Срок оценки: From enrollment to the end of treatment at 16 weeks.]
• Differentially methylated CpG sites (Δβ-value) [Срок оценки: From enrollment to the end of treatment at 16 weeks.]